Tirbanibulin clinical trials
Also written KX2-391 and Klisyri®.
How each study uses tirbanibulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tirbanibulin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Dec 2020 · KLISYRI · NDA 213189 (FDA, Drugs@FDA)
- European Union
- 16 Jul 2021 · Klisyri · EMEA/H/C/005183 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 6
Almirall, S.A. (4) · PharmaEssentia (3) · Medical University of Graz (2) · Athenex, Inc. (2) · Austin Institute for Clinical Research (1) · Kinex Pharmaceuticals Inc. (1) · University Hospital, Lille (1) · Centre Hospitalier Universitaire de Nice (1)
Often tested with
Tested in the same studies.
Cryotherapy (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test tirbanibulin.
- Nov 2026Tirbanibulin for Pediatric WartsPhase 4 · The Skin Center Dermatology Group
- Jul 2027A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpPhase 4 · Almirall, S.A.
Studies
Open first, then newest update. How each study uses tirbanibulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Tirbanubulin (Klisiry®) in the Treatment of Basal Cell CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de NiceNCT06112522Written as Tirbanibulin
- Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadNot yet recruitingPhase 3University Hospital, LilleNCT07273656Written as Cryotherapy + Tirbanibulin
- Tirbanibulin for Pediatric WartsRecruitingPhase 4The Skin Center Dermatology GroupNCT06791525Written as Tirbanibulin ointment 1%
- Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentRecruitingPhase 1/2Bruce Robinson, MDNCT07010692Written as Tirbanibulin ointment 1%
- A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisCompletedPhase 3Almirall, S.A.NCT06135415Written as Tirbanibulin
- KX01 Ointment Phase 1 Study in Patients With Plaque Type PsoriasisCompletedPhase 1PharmaEssentiaNCT05522816Written as KX01 0.01% (0.1 mg/g)
- A Study of Tirbanibulin on the Wellbeing of Participants With Actinic KeratosesCompletedPhase 4Almirall, S.A.NCT05741294Written as Tirbanibulin 2.5 mg ointment
- A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpActive, not recruitingPhase 4Almirall, S.A.NCT05387525Written as Tirbanibulin (Klisyri®) 10 mg/g ointment
- Proof of Concept Study to Access Superficial Basal Cell Carcinoma in AdultsCompletedPhase 2Austin Institute for Clinical ResearchNCT05713760Written as Tirbanibulin Ointment 1%
- Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the HandsWithdrawnPhase 4Medical University of GrazNCT06026358Written as Tirbanibulin
- A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or ScalpCompletedPhase 3PharmaEssentiaNCT05231044Written as KX01 ointment 1%
- A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic KeratosisCompletedPhase 3Almirall, S.A.NCT05279131Written as Tirbanibulin ointment 1%
- Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the FaceCompletedPhase 4Medical University of GrazNCT05900258Written as Tirbanibulin
- Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate CancerCompletedPhase 2Athenex, Inc.NCT01074138Written as KX2-391
- Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male SubjectsCompletedPhase 1PharmaEssentiaNCT05245578Written as KX01 ointment 1%
- Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)CompletedPhase 1Kinex Pharmaceuticals Inc.NCT01397799Written as KX2-391
- A Study of KX2-391 With Paclitaxel in Patients With Solid TumorsStatus unknownPhase 1/2Hanmi Pharmaceutical Company LimitedNCT01764087Written as KX2-391 and Paclitaxel
- Evaluation of KX2-391 in Patients With Advanced MalignanciesCompletedPhase 1Athenex, Inc.NCT00658970Written as KX2-391
Codes
What other systems call tirbanibulin · ClinicalTrials.gg INT001552
- MeSH (NLM) C000713668tirbanibulinOne source ClinicalTrials.gov
- UNII (FDA) 4V9848RS5GTIRBANIBULINConfirmed FDA, Wikidata
- RxNorm 2471078One source FDA
- Wikidata Q27888424tirbanibulinConfirmed FDA, Wikidata
- NCI Thesaurus C74077TirbanibulinOne source FDA
- DrugBank DB06137One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713668 | tirbanibulin | One source ClinicalTrials.gov |
| UNII (FDA) | 4V9848RS5G | TIRBANIBULIN | Confirmed FDA, Wikidata |
| RxNorm | 2471078 | — | One source FDA |
| Wikidata | Q27888424 | tirbanibulin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C74077 | Tirbanibulin | One source FDA |
| DrugBank | DB06137 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.